Skip to main content
Top
Published in: Virology Journal 1/2012

Open Access 01-12-2012 | Research

Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection

Authors: Yves Rivière, Thomas Montange, Geneviève Janvier, Caroline Marnata, Ludovic Durrieu, Marie-Laure Chaix, Maria Isaguliants, Odile Launay, Jean-Louis Bresson, Stanislas Pol

Published in: Virology Journal | Issue 1/2012

Login to get access

Abstract

The detection of hepatitis C virus (HCV)-specific T cell responses in HCV-uninfected, presumably unexposed, subjects could be due to an underestimation of the frequency of spontaneously resolving infections, as most acute HCV infections are clinically silent. To address this hypothesis, HCV-specific cellular immune responses were characterized, in individuals negative for an HCV PCR assay and humoral response, with (n = 32) or without (n = 33) risk of exposure to HCV. Uninfected volunteers (n = 20) with a chronically HCV-infected partner were included as positive controls for potential exposure to HCV and HCV infection, respectively. HCV-specific T cell responses in freshly isolated peripheral blood mononuclear cells were studied ex vivo by ELISPOT and CFSE-based proliferation assays using panels of HCV Core and NS3-derived peptides. A pool of unrelated peptides was used as a negative control, and a peptide mix of human cytomegalovirus, Epstein-Bar virus and Influenza virus as a positive control. Overall, 20% of presumably HCV-uninfected subject tested had detectable T-cell responses to the virus, a rate much higher than previous estimates of HCV prevalence in developed countries. This result would be consistent with unapparent primary HCV infections that either cleared spontaneously or remained undetected by conventional serological assays.
Appendix
Available only for authorised users
Literature
2.
go back to reference Semmo N, Barnes E, Taylor C, Kurtz K, Harcourt G, Smith N, et al.: T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005, 365: 327-329.PubMedCrossRef Semmo N, Barnes E, Taylor C, Kurtz K, Harcourt G, Smith N, et al.: T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005, 365: 327-329.PubMedCrossRef
3.
go back to reference Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, et al.: Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007,4(58):1-11. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, et al.: Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007,4(58):1-11.
4.
go back to reference Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al.: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature medicine 2000, 6: 578-582. 10.1038/75063PubMedCrossRef Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al.: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature medicine 2000, 6: 578-582. 10.1038/75063PubMedCrossRef
5.
go back to reference Widell A, Busch M: Exposed or not exposed-that is the question: evidence for resolving and abortive hepatitis C virus infections in blood donors. Transfusion 2009, 49: 1277-1281.PubMedCrossRef Widell A, Busch M: Exposed or not exposed-that is the question: evidence for resolving and abortive hepatitis C virus infections in blood donors. Transfusion 2009, 49: 1277-1281.PubMedCrossRef
6.
go back to reference Post JJ, Ratnarajah S, Llyod AR: Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009, 66: 733-756. 10.1007/s00018-008-8270-4PubMedCrossRef Post JJ, Ratnarajah S, Llyod AR: Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009, 66: 733-756. 10.1007/s00018-008-8270-4PubMedCrossRef
7.
go back to reference Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al.: Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004, 78: 11252-11258.CrossRef Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al.: Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004, 78: 11252-11258.CrossRef
8.
go back to reference Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KMC, Reichen J, et al.: Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999, 190: 169-176. 10.1084/jem.190.2.169PubMedPubMedCentralCrossRef Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KMC, Reichen J, et al.: Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999, 190: 169-176. 10.1084/jem.190.2.169PubMedPubMedCentralCrossRef
9.
go back to reference Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B: Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 2001, 75: 11392-11400. 10.1128/JVI.75.23.11392-11400.2001PubMedPubMedCentralCrossRef Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B: Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 2001, 75: 11392-11400. 10.1128/JVI.75.23.11392-11400.2001PubMedPubMedCentralCrossRef
10.
go back to reference Kennedy PT, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, et al.: The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology 2006, 43: 602-611. 10.1002/hep.21081PubMedCrossRef Kennedy PT, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, et al.: The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology 2006, 43: 602-611. 10.1002/hep.21081PubMedCrossRef
11.
go back to reference Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G: for the GERMIVIC Study Group. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepatitis 2006, 13: 775-782. 10.1111/j.1365-2893.2006.00742.xCrossRef Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G: for the GERMIVIC Study Group. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepatitis 2006, 13: 775-782. 10.1111/j.1365-2893.2006.00742.xCrossRef
12.
go back to reference Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, et al.: A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260: 157-172. 10.1016/S0022-1759(01)00535-XPubMedCrossRef Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, et al.: A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260: 157-172. 10.1016/S0022-1759(01)00535-XPubMedCrossRef
13.
go back to reference Thimme R, Neumann-Haefelin C, Boettler T, Blum HB: Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 2008, 389: 457-467.PubMedCrossRef Thimme R, Neumann-Haefelin C, Boettler T, Blum HB: Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 2008, 389: 457-467.PubMedCrossRef
14.
go back to reference Yusim K, Richardson R, Tao N, Szinger JJ, Funkhouser R, Korber B, et al.: HCV HCV immunology database: the Los Alamos Hepatitis C Immunology Database. Appl Bioinforma 2005, 4: 217-225. 10.2165/00822942-200504040-00002CrossRef Yusim K, Richardson R, Tao N, Szinger JJ, Funkhouser R, Korber B, et al.: HCV HCV immunology database: the Los Alamos Hepatitis C Immunology Database. Appl Bioinforma 2005, 4: 217-225. 10.2165/00822942-200504040-00002CrossRef
15.
go back to reference Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401: 708-712. 10.1038/44385PubMedCrossRef Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401: 708-712. 10.1038/44385PubMedCrossRef
16.
go back to reference McKinnon LR, Blake Ball T, Wachihi C, McLaren PJ, Waruk JLM, Mao X, et al.: Epitope cross-reactivity frequently differs between central and effector memory HIV-specific CD8-T cells. J Immunol 2007, 178: 3750-3756.PubMedCrossRef McKinnon LR, Blake Ball T, Wachihi C, McLaren PJ, Waruk JLM, Mao X, et al.: Epitope cross-reactivity frequently differs between central and effector memory HIV-specific CD8-T cells. J Immunol 2007, 178: 3750-3756.PubMedCrossRef
17.
go back to reference Bronowicki JP, Vetter D, Uhl G, Hudziak H, Uhrlacher A, Vetter JM, et al.: Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCVseronegatives spouses of HCV-infected patients. J Infect Dis 1997, 176: 518-527. 10.1086/517279PubMedCrossRef Bronowicki JP, Vetter D, Uhl G, Hudziak H, Uhrlacher A, Vetter JM, et al.: Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCVseronegatives spouses of HCV-infected patients. J Infect Dis 1997, 176: 518-527. 10.1086/517279PubMedCrossRef
18.
go back to reference Jackson M, Smith B, Bevitt DJ, Steward M, Toms GL, Bassendine MF, et al.: Comparison of cytotoxic T lymphocyte responses to Hepatitis C virus core protein in uninfected and infected individuals. J Med Virol 1999, 58: 239-246. 10.1002/(SICI)1096-9071(199907)58:3<239::AID-JMV9>3.0.CO;2-VPubMedCrossRef Jackson M, Smith B, Bevitt DJ, Steward M, Toms GL, Bassendine MF, et al.: Comparison of cytotoxic T lymphocyte responses to Hepatitis C virus core protein in uninfected and infected individuals. J Med Virol 1999, 58: 239-246. 10.1002/(SICI)1096-9071(199907)58:3<239::AID-JMV9>3.0.CO;2-VPubMedCrossRef
19.
go back to reference Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD: Hepatitis C virus-specific cytolytic T lymphocyte and T helper responses in seronegative persons. J Infect Dis 1997, 176: 859-867. 10.1086/516546PubMedCrossRef Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD: Hepatitis C virus-specific cytolytic T lymphocyte and T helper responses in seronegative persons. J Infect Dis 1997, 176: 859-867. 10.1086/516546PubMedCrossRef
20.
go back to reference Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al.: Presence of effector CD8+ T cells in Hepatitis C virus exposed healthy seronegative donors. J Immunol 1999, 162: 6681-6689.PubMed Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al.: Presence of effector CD8+ T cells in Hepatitis C virus exposed healthy seronegative donors. J Immunol 1999, 162: 6681-6689.PubMed
21.
go back to reference Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, et al.: Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009, 16: 10-20. 10.1111/j.1365-2893.2008.01016.xPubMedPubMedCentralCrossRef Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, et al.: Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009, 16: 10-20. 10.1111/j.1365-2893.2008.01016.xPubMedPubMedCentralCrossRef
22.
go back to reference Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al.: Clearance of hepatitis C viremia associated with cellular in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004, 189: 1846-1855. 10.1086/383279PubMedCrossRef Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al.: Clearance of hepatitis C viremia associated with cellular in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004, 189: 1846-1855. 10.1086/383279PubMedCrossRef
23.
go back to reference Hashem M, El-Karksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, et al.: Strong Hepatitis C Virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis 2011, 203: 854-861. 10.1093/infdis/jiq123PubMedPubMedCentralCrossRef Hashem M, El-Karksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, et al.: Strong Hepatitis C Virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis 2011, 203: 854-861. 10.1093/infdis/jiq123PubMedPubMedCentralCrossRef
24.
go back to reference Altschul SF, Madden TM, Schäffer AA, Zhang J, Zhang Z, Miller W, et al.: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997, 25: 3389-3402. 10.1093/nar/25.17.3389PubMedPubMedCentralCrossRef Altschul SF, Madden TM, Schäffer AA, Zhang J, Zhang Z, Miller W, et al.: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997, 25: 3389-3402. 10.1093/nar/25.17.3389PubMedPubMedCentralCrossRef
25.
go back to reference Horton H, Russell N, Moore E, Frank I, Baydo R, Havenar-Daughton C, et al.: Correlation between Interferon-γ Secretion and Cytotoxicity in Virus-Specific Memory T Cells. J Infect Dis 2004, 190: 1692-1696. 10.1086/424490PubMedCrossRef Horton H, Russell N, Moore E, Frank I, Baydo R, Havenar-Daughton C, et al.: Correlation between Interferon-γ Secretion and Cytotoxicity in Virus-Specific Memory T Cells. J Infect Dis 2004, 190: 1692-1696. 10.1086/424490PubMedCrossRef
26.
go back to reference Littaua RA, Oldstone MBA, Atakeda A, Ennis FA: A CD4+ Cytotoxic T-Lymphocyte Clone to a Conserved Epitope on Human Immunodeficiency Virus Type 1 p24: Cytotoxic Activity and Secretion of Interleukin-2 and Interleukin-6. J Virol 1992, 66: 608-611.PubMedPubMedCentral Littaua RA, Oldstone MBA, Atakeda A, Ennis FA: A CD4+ Cytotoxic T-Lymphocyte Clone to a Conserved Epitope on Human Immunodeficiency Virus Type 1 p24: Cytotoxic Activity and Secretion of Interleukin-2 and Interleukin-6. J Virol 1992, 66: 608-611.PubMedPubMedCentral
27.
go back to reference Demkowicz WE Jr, Littaua RA, Wang J, Ennis FA: Human Cytotoxic T-Cell Memory: Long-Lived Responses to Vaccinia Virus. J Virol 1996, 70: 2627-2631.PubMedPubMedCentral Demkowicz WE Jr, Littaua RA, Wang J, Ennis FA: Human Cytotoxic T-Cell Memory: Long-Lived Responses to Vaccinia Virus. J Virol 1996, 70: 2627-2631.PubMedPubMedCentral
28.
go back to reference Puissant-Lubrano B, Bossi P, Gay F, Crance JM, Bonduelle O, Garin D, et al.: + effector/memory CD4+ lymphocytes in humans + TNF-a Control of vaccinia virus skin lesions by long-term-maintained IFN-g. J Clin Invest 2010, 120: 1636-1644. 10.1172/JCI38506PubMedPubMedCentralCrossRef Puissant-Lubrano B, Bossi P, Gay F, Crance JM, Bonduelle O, Garin D, et al.: + effector/memory CD4+ lymphocytes in humans + TNF-a Control of vaccinia virus skin lesions by long-term-maintained IFN-g. J Clin Invest 2010, 120: 1636-1644. 10.1172/JCI38506PubMedPubMedCentralCrossRef
29.
go back to reference Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Pardo M, Carreno V: Cellular immune responses associated with occult hepatitis C virus infection in the liver. J Virol 2006, 80: 10972-10979. 10.1128/JVI.00852-06PubMedPubMedCentralCrossRef Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Pardo M, Carreno V: Cellular immune responses associated with occult hepatitis C virus infection in the liver. J Virol 2006, 80: 10972-10979. 10.1128/JVI.00852-06PubMedPubMedCentralCrossRef
30.
go back to reference Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, et al.: Occult hepatitis C infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004, 189: 7-14. 10.1086/380202PubMedCrossRef Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, et al.: Occult hepatitis C infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004, 189: 7-14. 10.1086/380202PubMedCrossRef
31.
go back to reference Poynard T, Lebray P, Ingiliz P, Varaut A, Ngo Y, Norha P, et al.: Prevalence of liver fibrosis and risk factors in a general population usng non-invasive biomarkers (Fibrotest). BMC Gastroenterol 2010, 10: 4. 10.1186/1471-230X-10-4CrossRef Poynard T, Lebray P, Ingiliz P, Varaut A, Ngo Y, Norha P, et al.: Prevalence of liver fibrosis and risk factors in a general population usng non-invasive biomarkers (Fibrotest). BMC Gastroenterol 2010, 10: 4. 10.1186/1471-230X-10-4CrossRef
32.
go back to reference Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461: 369-401.CrossRef Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461: 369-401.CrossRef
33.
go back to reference Thomas DL, Chloe L, Thio CL, Maureen P, Martin MP, Qi Y, Dongliang Ge D, O'hUigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Sharyne M, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington Mary: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461: 798-802. 10.1038/nature08463PubMedPubMedCentralCrossRef Thomas DL, Chloe L, Thio CL, Maureen P, Martin MP, Qi Y, Dongliang Ge D, O'hUigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Sharyne M, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington Mary: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461: 798-802. 10.1038/nature08463PubMedPubMedCentralCrossRef
34.
go back to reference Jensen DM, Pol S: IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int 2012, 32: 74-78.PubMedCrossRef Jensen DM, Pol S: IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int 2012, 32: 74-78.PubMedCrossRef
35.
go back to reference Janvier G, Chaix ML, Fontaine H, Bresson JL, Pol S, Rivière Y: The core-specific precursor T cell response is directed to the N-terminal and central parts of the protein and positively correlates to the viral load in chronically HCV-infected patients. Virology 2005, 340: 318-325. 10.1016/j.virol.2005.06.031PubMedCrossRef Janvier G, Chaix ML, Fontaine H, Bresson JL, Pol S, Rivière Y: The core-specific precursor T cell response is directed to the N-terminal and central parts of the protein and positively correlates to the viral load in chronically HCV-infected patients. Virology 2005, 340: 318-325. 10.1016/j.virol.2005.06.031PubMedCrossRef
36.
go back to reference Kuiken C, Mizokami M, Deleage G, Yusim K, Penin F, Shin-I T, et al.: Hepatitis C Databases, Principles and Utility to Researchers. Hepatology 2006, 143: 1157-1165.CrossRef Kuiken C, Mizokami M, Deleage G, Yusim K, Penin F, Shin-I T, et al.: Hepatitis C Databases, Principles and Utility to Researchers. Hepatology 2006, 143: 1157-1165.CrossRef
37.
go back to reference Kuiken C, Yusim K, Boykin L, Richardson R: The Los Alamos hepatitis C sequence database. Bioinformatics 2005, 21: 379-384. 10.1093/bioinformatics/bth485PubMedCrossRef Kuiken C, Yusim K, Boykin L, Richardson R: The Los Alamos hepatitis C sequence database. Bioinformatics 2005, 21: 379-384. 10.1093/bioinformatics/bth485PubMedCrossRef
38.
go back to reference Buseyne F, Catteau A, Scott-Algara D, Corre B, Porrot F, Rouzioux C, et al.: A Vaccinia-based Elispot assay for detection of CD8+ T cells from HIV-1 infected children. J Immunol Methods 2005, 298: 105-118. 10.1016/j.jim.2005.01.003PubMedCrossRef Buseyne F, Catteau A, Scott-Algara D, Corre B, Porrot F, Rouzioux C, et al.: A Vaccinia-based Elispot assay for detection of CD8+ T cells from HIV-1 infected children. J Immunol Methods 2005, 298: 105-118. 10.1016/j.jim.2005.01.003PubMedCrossRef
39.
go back to reference Lyons AB: Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000, 243: 147-154. 10.1016/S0022-1759(00)00231-3PubMedCrossRef Lyons AB: Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000, 243: 147-154. 10.1016/S0022-1759(00)00231-3PubMedCrossRef
Metadata
Title
Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection
Authors
Yves Rivière
Thomas Montange
Geneviève Janvier
Caroline Marnata
Ludovic Durrieu
Marie-Laure Chaix
Maria Isaguliants
Odile Launay
Jean-Louis Bresson
Stanislas Pol
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-9-76

Other articles of this Issue 1/2012

Virology Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.